Compare Appian Corp (APPN) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Ascendis Pharma A/S — how do they compare? Appian Corp trades at $34.57 (market cap $2.54B), while Ascendis Pharma A/S trades at $255.85 (market cap $16.67B). The key difference: Ascendis Pharma A/S is far larger — about 6.6× Appian Corp's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Appian Corp nearer its low. Which is the better fit depends on your goals.
| APPN | ASND | |
|---|---|---|
Market Cap | $2.54B | $16.67B |
Sector | Technology | Health |
52-Week High | $45.64 | $277.18 |
52-Week Low | $18.72 | $189.74 |
Enterprise Value | $2.67B | $17.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian Corporation (APPN) trades at $35.05, down 1.49% on the day, following a series of recent earnings beats. The stock exhibits a bullish technical trend with strong moving average support, though oscillators signal overbought conditions. Fundamentally, the company shows robust revenue growth, reaching $727 million in 2025, and has achieved positive net income after years of losses, yet maintains a negative shareholder equity position. Recent news highlights strategic AI partnerships and strong quarterly performance.
The outlook is cautiously optimistic, driven by AI-driven demand and enterprise growth, but significant risks persist, including high valuation multiples, negative equity, and intense competition. Analyst consensus is mixed, with a majority Hold rating, suggesting the stock may be fully valued near-term despite operational improvements.
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
